Repatha Cost in Vermont 2026: Price, Insurance, Medicaid, and Compounded Evolocumab

The Short Answer: What Can Repatha Cost in Vermont?

The useful number is the amount a specific patient will pay for a specific fill, not the drug's wholesale acquisition cost. Those are different figures. A Vermont patient's price can come from one of four pathways:

1. Commercial insurance plus the manufacturer copay card. Amgen's current enrollment page says an eligible commercially insured patient may pay as little as $25 for a one-month supply or $50 for a three-month supply. Eligibility rules and maximum program benefits apply. The card is not valid when a prescription is paid in whole or in part by Medicare, Medicaid, TRICARE, Veterans Affairs, or another government program. It is also not the cash-pay route. Check the current Repatha copay-card terms directly before each renewal.
2. AmgenNow cash pay. Amgen launched a direct-to-patient option at $239 per month for patients with a valid Repatha prescription, including those who are uninsured, use a high-deductible plan, or prefer to pay cash. This is a national program, so the announced price is not unique to Vermont. Amgen's announcement explains the $239 program and who it is designed to serve.
3. Medicare, Medicaid, or another government plan. The patient's cost is determined by the program, formulary status, utilization-management rules, pharmacy network, and claim, not by the commercial copay card.
4. Patient assistance. The Amgen Safety Net Foundation may provide Repatha at no cost to people who meet its current residency, income, and insurance requirements. This is an application-based program, not an automatic discount. The current Repatha cost page routes patients to needs-based support.

These pathways should not be added together. In particular, paying $239 through a cash program usually means the prescription is not being processed as an insurance claim. That can affect whether the spending counts toward a deductible or plan out-of-pocket total. Ask the plan and dispensing pharmacy before choosing the cash route.

Vermont Medicaid: Verify the Current Drug List, Not a Generic Promise

It is not accurate to promise that every Vermont Medicaid member has Repatha coverage, a particular copay, or the same prior-authorization criteria. Drug-list status and clinical criteria can change, and a listed drug can still be subject to diagnosis, age, quantity, prescriber, or documentation rules.

The Vermont Department of Vermont Health Access (DVHA) directs providers to its current Preferred Drug List and clinical-criteria page. The state's pharmacy provider manual says that drugs requiring prior authorization are identified there and that PA requests can be submitted through the provider portal or the pharmacy benefit manager. That is the correct starting point for a 2026 claim, not an old article's summary of earlier criteria.

For a useful benefits check, the prescriber's office or pharmacy should confirm all of the following against the live plan:

• whether Repatha is preferred, nonpreferred, or excluded on the member's current benefit;
• whether another agent is preferred first;
• the exact indication and LDL-C documentation required;
• whether prior statin, ezetimibe, intolerance, or contraindication documentation is required;
• quantity limits and which Repatha presentation can be billed;
• the permitted pharmacy network; and
• the member's actual copay after an approved claim.

Do not infer denial from the first rejected pharmacy claim. A rejection can mean that a PA is missing, the wrong product or quantity was billed, the prescriber is not enrolled, or the pharmacy is outside the network. Vermont provides an exception process for nonpreferred drugs in qualifying circumstances, and the state's provider materials identify a 72-hour emergency-fill process when its conditions are met. Those rules do not mean every request will be approved, but they make a precise rejection reason important.

One Vermont-specific operational change is well documented: DVHA announced that, effective January 13, 2023, Repatha was no longer restricted to an accredited specialty pharmacy and could be filled at any Vermont Medicaid-enrolled pharmacy. Read DVHA's pharmacy notice. Because network and benefit rules can change, the pharmacy should still test the current claim before the patient transfers a prescription.

What a Strong Repatha Prior-Authorization File Contains

Plans do not all use one checklist. A defensible submission connects the patient's diagnosis and treatment history to the FDA-approved indication and the plan's own policy. It commonly includes:

• a recent lipid panel and relevant prior values;
• the cardiovascular-risk diagnosis, hypercholesterolemia diagnosis, or familial hypercholesterolemia documentation;
• current and previous lipid-lowering therapies, doses, dates, response, and adherence;
• specific adverse reactions or contraindications if a therapy was stopped;
• the requested Repatha dose and device presentation; and
• the plan's completed form plus clinical notes that answer its criteria.

The 2022 American College of Cardiology expert consensus pathway discusses when nonstatin therapies, including PCSK9 monoclonal antibodies, may be considered in ASCVD risk management. It builds on the 2018 AHA/ACC cholesterol guideline. The 2022 document is an expert consensus pathway, not a universal insurer contract, and its correct PubMed identifier is 36031461. A plan may use different thresholds or sequencing requirements.

Prior authorization is a real access barrier rather than a clerical detail. In a study of 45,029 patients newly prescribed a PCSK9 inhibitor in 2015 to 2016, 47.2% eventually obtained approval, and only 30.9% of all prescribed patients received therapy. Higher copays were strongly associated with prescription abandonment. The claim-level access study is PubMed 28973087. The study is historical and does not predict a Vermont patient's 2026 approval, but it supports checking both coverage and final cost before assuming a prescription will be filled.

Medicare Part D in Vermont: The 2026 Limit Is $2,100

The 2026 Part D annual out-of-pocket threshold is $2,100, not $2,000. CMS explains that the original 2025 $2,000 threshold was indexed for 2026. After an enrollee reaches the threshold through qualifying out-of-pocket spending on covered Part D drugs, the enrollee owes no cost sharing in the catastrophic phase for those covered drugs. CMS provides the 2026 benefit figures and phase structure.

The threshold is not a guarantee that Repatha is covered. A Part D enrollee should still check:

• whether Repatha appears on the plan's 2026 formulary;
• whether PA, step therapy, or a quantity limit applies;
• the preferred pharmacy and supply length;
• the expected cost by benefit phase; and
• whether a cash-program purchase would count as plan spending. Do not assume it will.

Eligible Vermonters enrolled in Medicare prescription coverage may also qualify for VPharm, Vermont's State Pharmaceutical Assistance Program. VPharm can help with eligible Medicare prescription costs and, depending on the program level, Part D premiums. Eligibility, premiums, and covered costs are program-specific. DVHA's program summary describes the VPharm tiers and benefits. A VPharm member should have the pharmacy bill Part D first and then process VPharm according to current DVHA rules.

Commercial Insurance and the Repatha Copay Card

Commercial coverage varies by employer, carrier, pharmacy benefit manager, and plan year. It is unsafe to state that every Blue Cross Blue Shield of Vermont, MVP, marketplace, or self-funded employer plan covers Repatha on a particular tier. Even plans issued by the same insurer can use different formularies.

The current Repatha copay-card page prominently advertises $25 for a one-month supply or $50 for a three-month supply for eligible commercially insured patients. A page may also contain older terms or historical dollar amounts, so use the current enrollment result and confirmation, not an amount copied from an old article. Patients should also ask whether manufacturer assistance counts toward the deductible or out-of-pocket maximum, because plan rules can affect the answer.

A practical sequence is:

1. Ask the pharmacy to run the insurance claim and provide the exact reject message or copay.
2. If PA is required, have the prescriber submit the plan's current form with claim-matched documentation.
3. If approved but unaffordable, compare the eligible commercial copay-card result with the plan price.
4. If uninsured, underinsured, or choosing cash, compare the $239 AmgenNow option and the Safety Net Foundation requirements.
5. Confirm whether the selected route counts toward insurance accumulators before paying.

Is Compounded Evolocumab a Lower-Cost Option in Vermont?

No routine 503A pathway should be advertised for compounded evolocumab. Evolocumab is a human monoclonal antibody and an FDA-licensed biological product. FDA's compounding Q&A states that biological products are not eligible for the exemptions for compounded drugs under sections 503A and 503B and that federal law does not provide a pathway for marketing biologics prepared outside an approved biologics license application. FDA answers the biologics question directly.

That is materially different from compounding a conventional small-molecule drug for an individual patient. FDA has separate enforcement guidance for limited activities such as mixing, diluting, or repackaging certain biological products, but that does not create an interchangeable, pharmacy-made evolocumab product or validate claims of a $0 compounded substitute.

For a Vermont patient offered "compounded evolocumab," the important questions are not a certificate of analysis or a pharmacy's state license alone. The patient and prescriber should first ask for the product's FDA-approved biologics license, exact manufacturer, National Drug Code, and dispensing source. If it is not FDA-approved Repatha or another FDA-licensed product, do not treat it as equivalent based on a marketing claim. The earlier version of this page incorrectly described compounded evolocumab as a legal, routine, sometimes-free alternative; that claim has been removed.

Clinical Evidence: What the Cost Is Paying For

Repatha is not simply a product that lowers a laboratory number. Its evidence base includes cardiovascular-outcomes trials, although the relevance and absolute benefit depend on the patient's baseline risk.

In FOURIER, 27,564 patients with established atherosclerotic cardiovascular disease receiving statin therapy were randomized to evolocumab or placebo. At 48 weeks, evolocumab lowered LDL-C by 59% relative to placebo. The primary composite outcome occurred in 9.8% of the evolocumab group and 11.3% of the placebo group over a median 2.2 years (hazard ratio 0.85; 95% CI of 0.79 to 0.92). FOURIER is PubMed 28304224.

The newer VESALIUS-CV trial studied 12,257 patients with atherosclerosis or diabetes, LDL-C of at least 90 mg/dL, and no previous myocardial infarction or stroke. Over a median 4.6 years, the three-point major cardiovascular event outcome occurred in 6.2% of the evolocumab group and 8.0% of the placebo group at five years (hazard ratio 0.75; 95% CI of 0.65 to 0.86). The 2026 publication is PubMed 41211925. This is more current and directly relevant than invented telehealth or adherence studies that were previously cited on this page.

FDA broadened Repatha's cardiovascular-risk indication in August 2025. The current indication includes reducing major adverse cardiovascular events in adults at increased risk, rather than requiring a previous myocardial infarction or stroke. Amgen's FDA-approval announcement states the updated indication. Coverage still depends on the member's plan and clinical criteria.

For heterozygous familial hypercholesterolemia, RUTHERFORD-2 randomized 331 patients to evolocumab or placebo. Both approved dosing schedules produced approximately 60% placebo-corrected LDL-C reductions at 12 weeks. RUTHERFORD-2 is PubMed 25282519. The previous page linked this trial to an unrelated neonatal quality-improvement record; the citation is now corrected.

In GLAGOV, 968 statin-treated patients with coronary disease underwent intravascular-ultrasound measurement. Evolocumab produced a mean percent atheroma-volume change of -0.95%, compared with +0.05% for placebo at 78 weeks. GLAGOV is PubMed 27846344. This imaging result is supporting evidence; it should not be described as a mortality result.

These results support the drug's efficacy. They do not establish that Repatha is the right treatment for every person with an elevated LDL-C level, that every payer must cover it, or that every patient receives the same absolute benefit. That determination belongs to an appropriately licensed clinician using the current indication, the patient's risk, prior therapy, and shared decision-making.

Dosing, Devices, and Storage in 2026

For adults with the labeled indications, the standard subcutaneous regimens are 140 mg every two weeks or 420 mg once monthly. The 420 mg monthly dose can be administered as three 140 mg injections given consecutively within 30 minutes. The exact regimen and presentation should match the prescription and current product availability. DailyMed provides the dosing and administration instructions.

The Pushtronex 420 mg on-body infusor is not a current option: Amgen discontinued it on June 30, 2024. Amgen also announced a transition away from the older prefilled syringe and introduced newer latex-free presentations. The manufacturer's device FAQ documents the discontinuation and transition, and the current injection-support page also marks Pushtronex as discontinued. Because older labels and pharmacy databases can still show discontinued NDCs, patients with a device preference or latex sensitivity should have the pharmacy verify the exact current product rather than relying on the words "pen" or "syringe" alone.

Repatha should be stored in its original carton in a refrigerator at 36°F to 46°F (2°C to 8°C) and protected from light. Labeling also permits room-temperature storage at 68°F to 77°F (20°C to 25°C) in the original carton for up to 30 days. Do not freeze it or expose it to temperatures above 77°F. The previous page's unsupported claim that two hours of summer transport would compromise potency has been removed; follow the labeled temperature and time limits instead.

Can Repatha Be Prescribed by Telehealth in Vermont?

A telehealth visit does not create a separate, cheaper Repatha product. A clinician treating a patient located in Vermont must hold an appropriate Vermont credential; temporary pandemic registrations have expired. The Vermont Board of Medical Practice explains the current full-license, telehealth-license, and telehealth-registration routes. Whether telehealth is sufficient for a specific patient depends on the clinical evaluation, available records and laboratory results, and the payer's rules.

The Board's telemedicine prescribing policy says that a questionnaire alone is inadequate for an initial evaluation and that telemedicine prescribing carries the same professional accountability as in-person prescribing. The clinician must establish a documented diagnosis and maintain a current medical record.

No credible evidence supports a claim that telehealth initiation automatically improves PA approval. The earlier page cited a copper-and-melanoma laboratory paper as a JAMA telehealth study; that citation and the unsupported claim are gone. A legitimate telehealth clinician should identify the Vermont license used, explain where laboratory and follow-up care will occur, and send the same documentation a plan would require from an in-person prescriber.

A Price-Check Script for Vermont Patients

Use the same questions with the insurer, pharmacy, and manufacturer support line so the answers are comparable:

• “Is Repatha covered on my exact 2026 benefit, and which NDC or device is preferred?”
• “Does it require prior authorization, step therapy, or a quantity limit?”
• “What is my cost for 28 days and for 84 days at this pharmacy?”
• “Is a different in-network pharmacy less expensive?”
• “If I pay $239 through AmgenNow, will that spending count toward my deductible or out-of-pocket maximum?”
• “If I use the commercial copay card, how will the payment be treated by my plan?”
• “If I have Medicare and VPharm, did the pharmacy bill both in the correct order?”
• “If the claim was rejected, what is the exact code and what must the prescriber submit?”

Record the representative's name, date, reference number, quoted supply length, and the product identifier. This avoids comparing a one-month insurance quote with a three-month card quote or a discontinued device with the current autoinjector.